- Home
- ERAS vs CROX Comparison
ERAS vs CROX Comparison
Compare ERAS & CROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | CROX |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ERAS | CROX |
|---|---|---|
| Price | $16.98 | $159.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | $24.11 | ★ $164.67 |
| AVG Volume (30 Days) | ★ 4.5M | 1.3M |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ 11.32 |
| Revenue | N/A | ★ $4,040,647,000.00 |
| Revenue This Year | N/A | $3.37 |
| Revenue Next Year | N/A | $3.80 |
| P/E Ratio | ★ N/A | $14.15 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.46 | $73.21 |
| 52 Week High | $24.28 | $161.88 |
Technical Indicators
Market Signals| Indicator | ERAS | CROX |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 73.05 |
| Support Level | $13.19 | $114.98 |
| Resistance Level | $18.71 | $161.88 |
| Average True Range (ATR) | 1.14 | 5.54 |
| MACD | 0.24 | 2.42 |
| Stochastic Oscillator | 88.53 | 94.66 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable operating segments of the company are the Crocs Brand and the HEYDUDE Brand. The company derives maximum revenue from the Crocs brand segment.